Results 11 to 20 of about 269,235 (359)

Anticoagulants and Osteoporosis [PDF]

International Journal of Molecular Sciences, 2019
Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong
S. Signorelli, Salvatore Scuto, Elisa Marino, M. Giusti, A. Xourafa, A. Gaudio   +5 more
semanticscholar   +4 more sources

Anticoagulants for people hospitalised with COVID-19.

Cochrane Database of Systematic Reviews, 2022
BACKGROUND The primary manifestation of coronavirus disease 2019 (COVID-19) is respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and thromboembolic events, such as pulmonary embolism, deep vein thrombosis, or ...
Ronald Lg Flumignan, V. T. Civile, J. D. D. S. Tinôco, P. I. Pascoal, L. L. Areias, C. Matar, B. Tendal, V. Trevisani, Á. Atallah, L. C. Nakano   +9 more
semanticscholar   +1 more source

Factor XI as a Target for New Anticoagulants

Hämostaseologie, 2021
Despite advances in anticoagulant therapy, thrombosis remains the leading cause of morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first anticoagulants to be used successfully for the prevention and treatment of ...
J. Fredenburgh, J. Weitz
semanticscholar   +1 more source

Antiviral anticoagulation [PDF]

Research and Practice in Thrombosis and Haemostasis, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel envelope virus that causes coronavirus disease 2019 (COVID-19). Hallmarks of COVID-19 are a puzzling form of thrombophilia that has elevated D-dimer but only modest effects on other parameters of coagulopathy.
Pryzdial, Edward L. G., Sutherland, Michael R., Lin, Bryan H., Horwitz, Marc   +3 more
openaire   +3 more sources

Necrotizing Pancreatitis: To Anticoagulate or Not to Anticoagulate?

Cureus, 2022
Necrotizing pancreatitis is an inflammatory process that poses a strong risk of systemic venous thromboembolism. However, it is often challenging to opt for systemic anticoagulation since the disease is also associated with an increased risk of hemorrhage.
Abi-Saleh, Simon P, Miller, Ethan A, Magge, Anil, Perez, Mario   +3 more
openaire   +2 more sources

Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

Journal of Thrombosis and Haemostasis, 2020
Clarity and guidance is required with regard to the use of direct oral anticoagulants in antiphospholipid syndrome (APS) patients, within the confines of the recent European Medicines Agency recommendations, discrepant recommendations in other ...
S. Zuily, H. Cohen, D. Isenberg, S. Woller, M. Crowther, V. Dufrost, D. Wahl, C. Doré, A. Cuker, M. Carrier, V. Pengo, K. Devreese   +11 more
semanticscholar   +1 more source

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

European Heart Journal, 2018
The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation ...
J. Steffel, P. Verhamme, T. Potpara, P. Albaladéjo, M. Antz, L. Desteghe, K. Haeusler, J. Oldgren, H. Reinecke, V. Roldán-Schilling, N. Rowell, P. Sinnaeve, R. Collins, A. Camm, H. Heidbüchel, G. Lip, J. Weitz, L. Fauchier, D. Lane, G. Boriani, A. Goette, R. Keegan, R. Macfadyen, C. Chiang, B. Joung, W. Shimizu   +25 more
semanticscholar   +1 more source

Limb ischemia in patients with COVID-19

Jornal Vascular Brasileiro, 2021
This narrative review covers the life-threatening thromboembolic events associated with SARS-CoV-2 infection/COVID-19. It addresses the physical changes that cause vascular and arterial damage to limbs, laboratory management of coagulation, and ...
Julio Cesar Peclat de Oliveira, Walter Jr. Boim Araujo, Sergio Quilici Belczak, Fabiano Luiz Erzinger, Lucas Maia Peclat de Oliveira, Marcos Arêas Marques, Lucas Mansano Sarquis, Bianca Gutfilen   +7 more
doaj   +1 more source

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

Europace, 2015
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al.
H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H. Diener, W. Hacke, J. Oldgren, P. Sinnaeve, A. Camm, Paulus Kirchhof, Paulus Kirchhof   +10 more
semanticscholar   +1 more source

Anticoagulation in the Elderly [PDF]

Pharmaceuticals, 2010
Management of anticoagulation in elderly patients represents a particularly challenging issue. Indeed, this patient population is at high thromboembolic risk, but also at high hemorrhagic risk. Assessment of the benefit-risk balance of anticoagulation is the key point when decisions are made about introducing and/or continuing such treatments in the ...
Robert-Ebadi, Helia, Righini, Marc Philip   +1 more
openaire   +3 more sources